Gilead’s new drug is even pricier than Sovaldi By: MarketWatch October 10, 2014 at 15:12 PM EDT Gilead’s new hepatitis C drug is even pricier than its $1,000-a-day Sovaldi. Read More >> Related Stocks: Gilead Sciences